66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05174221 (ClinicalTrials.gov) | November 9, 2022 | 14/12/2021 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy | A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy | Kidney Disease | Drug: Mezagitamab | Takeda | NULL | Recruiting | 18 Years | N/A | All | 16 | Phase 1 | United States;Australia;Belgium;China;Hungary;Italy;Japan;Korea, Republic of;Serbia;Singapore;Spain;Taiwan;United Kingdom |
| 2 | JPRN-jRCT2011220009 | 17/07/2022 | 15/06/2022 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy | A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy | Kidney Disease | TAK-079 (Mezagitamab) Mezagitamab, subcutaneous injection, once weekly for 8 weeks then once every 2 weeks for 16 weeks in the Main Study. Same dosing regimen will be repeated in LTE Retreatment Period. | Nishizawa Atsushi | NULL | Recruiting | >= 18age old | Not applicable | Both | 16 | Phase 1 | Australia;China;Spain;Italy;South Korea;Serbia;Singapore;Taiwan;USA;Belgium;Hungary;UK;Japan |